DE602006020294D1 - Heterozyklische verbindung - Google Patents

Heterozyklische verbindung

Info

Publication number
DE602006020294D1
DE602006020294D1 DE602006020294T DE602006020294T DE602006020294D1 DE 602006020294 D1 DE602006020294 D1 DE 602006020294D1 DE 602006020294 T DE602006020294 T DE 602006020294T DE 602006020294 T DE602006020294 T DE 602006020294T DE 602006020294 D1 DE602006020294 D1 DE 602006020294D1
Authority
DE
Germany
Prior art keywords
heterocyclic
connection
heterocyclic connection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006020294T
Other languages
English (en)
Inventor
Hiroshi Yamashita
Jun Matsubara
Hideaki Kuroda
Nobuaki Ito
Shin Miyamura
Tatsuyoshi Tanaka
Shinichi Taira
Tae Fukushima
Haruka Takahashi
Takeshi Kuroda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of DE602006020294D1 publication Critical patent/DE602006020294D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
DE602006020294T 2005-08-31 2006-08-31 Heterozyklische verbindung Active DE602006020294D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005251055 2005-08-31
PCT/JP2006/317704 WO2007026959A2 (en) 2005-08-31 2006-08-31 Derivatives of 4-piperazin-1-yl-4-benz0 [b] thiophene suitable for the treatment of cns disorders

Publications (1)

Publication Number Publication Date
DE602006020294D1 true DE602006020294D1 (de) 2011-04-07

Family

ID=37709698

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006020294T Active DE602006020294D1 (de) 2005-08-31 2006-08-31 Heterozyklische verbindung

Country Status (26)

Country Link
US (3) US8071600B2 (de)
EP (4) EP2284169B1 (de)
JP (1) JP4785677B2 (de)
KR (2) KR20100063807A (de)
CN (4) CN102558140A (de)
AR (1) AR055203A1 (de)
AT (4) ATE557021T1 (de)
AU (2) AU2006285607B2 (de)
BR (1) BRPI0615140A2 (de)
CA (1) CA2620688C (de)
CY (1) CY1111671T1 (de)
DE (1) DE602006020294D1 (de)
DK (1) DK1919907T5 (de)
ES (4) ES2362961T3 (de)
HK (1) HK1119707A1 (de)
IL (1) IL189383A (de)
MX (1) MX2008002736A (de)
MY (1) MY145670A (de)
PL (1) PL1919907T3 (de)
PT (1) PT1919907E (de)
RU (1) RU2415854C2 (de)
SG (1) SG155180A1 (de)
SI (1) SI1919907T1 (de)
TW (1) TWI329641B (de)
WO (1) WO2007026959A2 (de)
ZA (1) ZA200801888B (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004000260T2 (de) 2003-07-22 2006-08-24 Arena Pharmaceuticals, Inc., San Diego Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
PE20061130A1 (es) 2004-11-19 2007-01-05 Arena Pharm Inc Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a
EP2009005A4 (de) 2006-04-19 2010-06-02 Astellas Pharma Inc Azolcarbonsäureamidderivat
EP3395816A1 (de) 2006-05-18 2018-10-31 Arena Pharmaceuticals, Inc. Ether, sekundäre amine und derivate davon als modulatoren des 5-ht2a-serotonin-rezeptors zur behandlung damit zusammenhängender erkrankungen
ES2536762T3 (es) 2006-05-18 2015-05-28 Arena Pharmaceuticals, Inc. Aminas primarias y sus derivados como moduladores del receptor de la serotonina 5-HT2A útiles para el tratamiento de trastornos relacionados con este
CA2646081C (en) 2006-05-18 2017-06-27 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor
TWI329102B (en) * 2006-08-15 2010-08-21 Nat Health Research Institutes Thiourea compounds and method for inhibiting hepatitis c virus infection
WO2008020306A2 (en) * 2006-08-18 2008-02-21 Pfizer Products Inc. Isoindole derivatives
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
US20080186971A1 (en) * 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
EP1972628A1 (de) * 2007-03-21 2008-09-24 Schwarz Pharma Ag Indolizine und aza-analoge Derivate davon als CNS-aktive Verbindungen
US7985763B2 (en) * 2007-04-10 2011-07-26 National Health Research Institutes Hepatitis C virus inhibitors
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
TW200848016A (en) * 2007-06-08 2008-12-16 Nat Health Research Institutes Thiourea compound and composition of treating hepatitis C virus infection
US8420680B2 (en) * 2007-06-29 2013-04-16 Emory University NMDA receptor antagonists for neuroprotection
WO2009023253A2 (en) 2007-08-15 2009-02-19 Arena Pharmaceuticals Inc. IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
JPWO2009025265A1 (ja) * 2007-08-21 2010-11-25 塩野義製薬株式会社 ピペラジン誘導体
RU2461551C2 (ru) 2007-10-24 2012-09-20 Астеллас Фарма Инк. Азолкарбоксамидное соединение или его фармацевтически приемлемая соль
EP2225235B1 (de) * 2007-10-29 2017-09-06 Merck Sharp & Dohme Corp. Thiazolcarbonsäureamidderivate und deren verwendung zur behandlung von krebs
EP2254884B1 (de) * 2008-02-15 2013-05-01 F. Hoffmann-La Roche AG 3-alkyl-piperazin-derivate und anwendungen davon
CN101952259B (zh) 2008-02-22 2013-07-03 大塚制药株式会社 苯并二氮杂*化合物及药物组合物
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US8198284B2 (en) * 2008-04-30 2012-06-12 National Health Research Institutes Treatment of neurodegenerative disorders with thiourea compounds
EP2296658A4 (de) * 2008-05-09 2014-01-15 Univ Emory Nmda-rezeptor-antagonisten zur behandlung von neuropsychiatrischen erkrankungen
US8703761B2 (en) * 2008-07-15 2014-04-22 Novartis Ag Organic compounds
WO2010012121A1 (zh) * 2008-07-28 2010-02-04 江苏国华投资有限公司 芳烷基哌啶（嗪）衍生物及其在治疗精神分裂症中的应用
BRPI0917704A2 (pt) * 2008-09-01 2016-02-16 Neurosearch As composto, composição farmacêutica, e, uso de um composto químico
ES2666324T3 (es) 2008-10-28 2018-05-04 Arena Pharmaceuticals, Inc. Composiciones de un modulador del receptor de serotonina 5-HT2A útiles para el tratamiento de trastornos relacionados con el mismo
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
PE20120061A1 (es) * 2008-12-19 2012-02-19 Boehringer Ingelheim Int Derivados de pirimidina como antagonistas del receptor ccr2
US8748623B2 (en) 2009-02-17 2014-06-10 Syntrix Biosystems, Inc. Pyridinecarboxamides as CXCR2 modulators
TWI481601B (zh) * 2009-08-21 2015-04-21 Otsuka Pharma Co Ltd 含氮化合物及藥學組成物
RU2553676C2 (ru) * 2009-08-21 2015-06-20 Оцука Фармасьютикал Ко., Лтд. СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНОГО БЕНЗО[b][1,4]ДИАЗЕПИН-2,4-ДИОНА
PT3091012T (pt) 2009-12-17 2018-06-27 Centrexion Therapeutics Corp Antagonistas do receptor ccr2 e suas utilizações
US8980891B2 (en) 2009-12-18 2015-03-17 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
WO2011109679A2 (en) * 2010-03-05 2011-09-09 Amira Pharmaceuticals, Inc. Inhibitors of 5-lipoxygenase
JP2013526507A (ja) 2010-05-12 2013-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用
US8946218B2 (en) 2010-05-12 2015-02-03 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
JP5636094B2 (ja) 2010-05-25 2014-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体アンタゴニスト
EP2576538B1 (de) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH Neue CCR2-Antagonisten
AU2011293612B2 (en) 2010-08-23 2015-11-26 Syntrix Biosystems Inc. Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators
CN102206214B (zh) * 2011-04-07 2014-03-12 华中科技大学 苯并吡喃酮类衍生物及其应用
JP5786258B2 (ja) 2011-07-15 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規かつ選択的なｃｃｒ２拮抗薬
AR088352A1 (es) * 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US9951088B2 (en) 2012-05-09 2018-04-24 Sunovion Pharmaceuticals Inc. D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders
WO2014085208A1 (en) * 2012-11-27 2014-06-05 Merck Sharp & Dohme Corp. 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
US9745284B2 (en) * 2013-03-08 2017-08-29 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-ether orexin receptor antagonists
US10273243B2 (en) * 2013-03-14 2019-04-30 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
CN104059046B (zh) * 2013-03-18 2017-02-08 江苏恩华药业股份有限公司 黄酮类衍生物及其应用
CN104447723A (zh) * 2014-11-28 2015-03-25 瑞阳制药有限公司 7-(4-(4-(苯并[b]噻吩基)-1-哌嗪基)丁氧基)-2(1H)-喹啉酮的制备方法
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
MX2017017177A (es) 2015-07-02 2018-11-09 Centrexion Therapeutics Corp Citrato de (4-((3r,4r)-3-metoxitetrahidro-piran-4-ilamino)piperidi n-1-il)(5-metil-6-(((2r,6s)-6-(p-tolil)tetrahidro-2h-piran-2-il)m etilamino)pirimidin-4il) metanona.
RU2018103338A (ru) 2015-07-15 2019-08-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием
CN106749219A (zh) 2015-11-20 2017-05-31 江苏恩华药业股份有限公司 一种内酰胺类衍生物及其应用
EP3397636B1 (de) 2015-12-28 2021-08-04 Honour (R&D) Verfahren zur herstellung von chinolin-2(1h)-on-derivaten
CN112125896B (zh) * 2020-09-29 2021-10-29 湖南省湘中制药有限公司 一种抗精神病药依匹哌唑电化学制备方法
CN112079812B (zh) * 2020-09-29 2021-08-06 浙江大学 哌唑类抗精神病药物关键中间体及其电还原方法
WO2022093849A1 (en) * 2020-10-27 2022-05-05 Arena Pharmaceuticals, Inc. Pyrimidine derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
CN115772175A (zh) * 2021-09-07 2023-03-10 中国科学院分子细胞科学卓越创新中心 噻吩并环化合物及其制备方法和应用
WO2023144764A1 (en) 2022-01-29 2023-08-03 Suven Life Sciences Limited Benzoisothiazole and benzoisoxazole compounds for the treatment of mental disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2960178D1 (en) * 1978-06-06 1981-04-09 Hoechst Ag New substituted phenylpiperazine derivatives, pharmaceutical compositions containing them and process for their preparation
JPS5649361A (en) 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
CA2004670A1 (en) * 1988-12-08 1990-06-08 Jan Hartog Anxiolytically active piperazine derivatives
WO1991000863A1 (en) 1989-07-07 1991-01-24 Pfizer Inc. Heteroaryl piperazine antipsychotic agents
CA2067475C (en) 1991-05-08 2000-10-10 Yasuo Oshiro Carbostyril derivatives and their use
US5240927A (en) * 1992-05-19 1993-08-31 Hoechst-Roussel Pharmaceuticals Incorporated Benzo[β]thiophen-3-yl piperazines as antipsychotic agents
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
EP0732332B1 (de) * 1995-03-17 2001-12-19 Aventis Pharmaceuticals Inc. Substituierte Benzylthienylpiperazine, ihre Anwendung als Arzneimittel und Verfahren für ihre Herstellung
FR2740134B1 (fr) 1995-10-18 1998-01-09 Pf Medicament Derives d'amines cycliques d'aryl-piperazines, leur preparation et les compositions pharmaceutiques les contenant
EP0934932A4 (de) 1996-08-22 2002-06-26 Meiji Seika Kaisha Chinolinderivate und psychotropes mittel
FR2761068B1 (fr) 1997-03-20 1999-04-23 Synthelabo Derives de piperazin-4-ylthieno[3,2-c]pyridin-4-yl-2- carboxamide, leur preparation et leur application en therapeutique
AU777594B2 (en) 1999-05-24 2004-10-21 Mitsubishi Pharma Corporation Phenoxypropylamine compounds
AR027133A1 (es) * 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de heteroarilo, su preparacion y uso.
AR027134A1 (es) * 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de indol.
JP4497815B2 (ja) 2001-02-16 2010-07-07 アベンティス・ファーマスーティカルズ・インコーポレイテツド 新規な複素環式アミド誘導体およびドーパミンｄ３受容体リガンドとしてのその使用
US6982332B2 (en) * 2001-06-07 2006-01-03 Wayne State University Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering CNS activity
DE60206043T2 (de) * 2001-06-29 2006-06-29 H. Lundbeck A/S, Valby Neue indolderivate
JP2006503106A (ja) * 2002-09-17 2006-01-26 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 統合失調症を処置するためのヘテロ環式置換ピペラジン
CA2500115A1 (en) 2002-09-26 2004-04-08 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
GB0227240D0 (en) * 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物

Also Published As

Publication number Publication date
TWI329641B (en) 2010-09-01
KR20100063807A (ko) 2010-06-11
CN101258147B (zh) 2012-03-21
HK1119707A1 (en) 2009-03-13
EP2287162B1 (de) 2012-05-09
EP2284169A1 (de) 2011-02-16
ATE557022T1 (de) 2012-05-15
ZA200801888B (en) 2009-07-29
AU2006285607B2 (en) 2010-02-25
RU2415854C2 (ru) 2011-04-10
ES2362961T3 (es) 2011-07-15
SG155180A1 (en) 2009-09-30
PL1919907T3 (pl) 2011-07-29
MY145670A (en) 2012-03-15
KR20080033446A (ko) 2008-04-16
CN102850336A (zh) 2013-01-02
CY1111671T1 (el) 2015-10-07
ATE557021T1 (de) 2012-05-15
CA2620688C (en) 2014-03-25
EP2287161A1 (de) 2011-02-23
US20120028920A1 (en) 2012-02-02
EP1919907B9 (de) 2012-01-18
IL189383A (en) 2013-03-24
EP2287162A1 (de) 2011-02-23
PT1919907E (pt) 2011-03-23
MX2008002736A (es) 2008-03-26
ES2383948T3 (es) 2012-06-27
WO2007026959A3 (en) 2007-08-16
IL189383A0 (en) 2008-06-05
CA2620688A1 (en) 2007-03-08
ES2382445T3 (es) 2012-06-08
US8598162B2 (en) 2013-12-03
ATE499369T1 (de) 2011-03-15
JP4785677B2 (ja) 2011-10-05
DK1919907T3 (da) 2011-04-18
JP2007091733A (ja) 2007-04-12
AU2010200362A1 (en) 2010-02-18
DK1919907T5 (da) 2011-09-12
EP2287161B1 (de) 2012-05-09
SI1919907T1 (sl) 2011-05-31
EP2284169B1 (de) 2012-03-14
EP1919907A2 (de) 2008-05-14
ATE549330T1 (de) 2012-03-15
AU2006285607A1 (en) 2007-03-08
BRPI0615140A2 (pt) 2010-01-12
KR101008873B1 (ko) 2011-01-19
ES2362961T9 (es) 2012-02-13
AR055203A1 (es) 2007-08-08
ES2383949T3 (es) 2012-06-27
CN102558140A (zh) 2012-07-11
CN101258147A (zh) 2008-09-03
CN102702182A (zh) 2012-10-03
US20140031334A1 (en) 2014-01-30
RU2008112224A (ru) 2009-10-10
US20090264404A1 (en) 2009-10-22
TW200800937A (en) 2008-01-01
WO2007026959A2 (en) 2007-03-08
EP1919907B1 (de) 2011-02-23
US8071600B2 (en) 2011-12-06

Similar Documents

Publication Publication Date Title
DE602006020294D1 (de) Heterozyklische verbindung
ATE408603T1 (de) Pyrazolylcarboxanilide
CR9974A (es) Gavión
DE502006003394D1 (de) Lehnenklappung
DK1937650T3 (da) Heterocykliske forbindelser
DE502006008475D1 (de) Wasserpumpenflügelrad
DK1885966T3 (da) Forbedret hoved-t-forbindelse
DE502006005667D1 (de) Gelenklager
ATE549324T1 (de) Tetrahydrobenzoxazine
DE602006010581D1 (de) 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate
DE502006005768D1 (de) Hydrolysestabilisatorformulierungen
DE502006006857D1 (de) Wingungserregern
DK1971588T3 (da) Tiglien-3-onderivater
DE502005005839D1 (de) Feldgeerät
DE502006001397D1 (de) Lagerbuchse
ATE485368T1 (de) Hiv - impfung
DE502006004302D1 (de) Verschlusskappe
DE502006001004D1 (de) Hydrolager
DE102005052834B8 (de) Punktschweißklebverbindung
ATE541837T1 (de) Oxaphenanthren-derivate
DE502006003210D1 (de) Nohydrogenpolysiloxanen
DE102006033170A8 (de) Einfassnähmaschine
DE502006002822D1 (de) Ges